Anastrozole Tablet
Product Images NDC 68071-5203

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68071-5203). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5203 3)

Label for Anastrozole 1 mg oral tablets by NuCare Pharmaceuticals, Inc. The label indicates a bottle containing 30 tablets. It includes NDC 68071-5203-3 and manufacturer information. The label directs to see the manufacturer's label for full list of ingredients and has standard warnings and storage instructions.*

FDA Label Image

Figure 1 (Anastrozole Fig1)

A survival graph illustrating disease-free survival over time in months for two randomized treatments: anastrozole and tamoxifen. The vertical axis shows the proportion of patients alive and disease-free, and the horizontal axis represents time in months, with corresponding patient numbers at risk listed below.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A Kaplan-Meier survival curve chart comparing disease-free survival over 96 months between two randomized treatments: anastrozole and tamoxifen. The Y-axis shows the proportion alive and disease-free, while the X-axis represents time in months. The chart includes a table below showing the number of patients at risk at various intervals for each treatment group.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

A line graph comparing the proportion of patients remaining event-free over time up to 120 months for two treatments: Anastrozole and Tamoxifen. The x-axis represents time to event in months, and the y-axis shows the proportion event-free. Below the graph, the number of patients at risk is listed at various time points for each treatment group.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

A Kaplan-Meier survival curve chart comparing the proportion of patients remaining event-free over time (in months) between two treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The x-axis represents time to event in months (0 to 120), and the y-axis represents the proportion event-free (0.50 to 1.00). Below the graph is a table showing the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

A line graph comparing the proportion of patients not progressing over time (months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, spanning 0 to 32, and the y-axis shows the proportion not progressing, from 0 to 1. The graph includes a patient risk table for each treatment group at specific time points.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A line graph comparing the proportion of patients not progressing over time in months between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis shows the proportion not progressed, with both treatment lines gradually declining over time.*

FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical structure of Anastrozole, showing a benzene ring substituted with two cyanide groups and two methyl groups, and linked to a 1,2,4-triazole ring. The diagram represents the molecular structure of the active ingredient Anastrozole.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.